FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200420384> ?p ?o ?g. }

• W4200420384 abstract "With the emergence of the delta variant, the United States experienced a rapid increase in Covid-19 cases in 2021. We estimated the risk of breakthrough infection and death by month of vaccination as a proxy for waning immunity during a period of delta variant predominance.Covid-19 case and death data from 15 U.S. jurisdictions during January 3 to September 4, 2021 were used to estimate weekly hazard rates among fully vaccinated persons, stratified by age group and vaccine product. Case and death rates during August 1 to September 4, 2021 were presented across four cohorts defined by month of vaccination. Poisson models were used to estimate adjusted rate ratios comparing the earlier cohorts to July rates.During August 1 to September 4, 2021, case rates per 100,000 person-weeks among all vaccine recipients for the January to February, March to April, May to June, and July cohorts were 168.8 (95% confidence interval [CI], 167.5 to 170.1), 123.5 (95% CI, 122.8 to 124.1), 83.6 (95% CI, 82.9 to 84.3), and 63.1 (95% CI, 61.6 to 64.6), respectively. Similar trends were observed by age group for BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccine recipients. Rates for the Ad26.COV2.S (Janssen-Johnson & Johnson) vaccine were higher; however, trends were inconsistent. BNT162b2 vaccine recipients 65 years of age or older had higher death rates among those vaccinated earlier in the year. Protection against death was sustained for the mRNA-1273 vaccine recipients. Across age groups and vaccine types, people who were vaccinated 6 months ago or longer (January-February) were 3.44 (3.36 to 3.53) times more likely to be infected and 1.70 (1.29 to 2.23) times more likely to die from COVID-19 than people vaccinated recently in July 2021.Our study suggests that protection from SARS-CoV-2 infection among all ages or death among older adults waned with increasing time since vaccination during a period of delta predominance. These results add to the evidence base that supports U.S. booster recommendations, especially for older adults vaccinated with BNT162b2 and recipients of the Ad26.COV2.S vaccine. (Funded by the Centers for Disease Control and Prevention.)." @default.
• W4200420384 created "2021-12-31" @default.
• W4200420384 creator A5000071831 @default.
• W4200420384 creator A5010709441 @default.
• W4200420384 creator A5011801139 @default.
• W4200420384 creator A5012143831 @default.
• W4200420384 creator A5014583094 @default.
• W4200420384 creator A5016764092 @default.
• W4200420384 creator A5017019372 @default.
• W4200420384 creator A5017417020 @default.
• W4200420384 creator A5021758604 @default.
• W4200420384 creator A5023912273 @default.
• W4200420384 creator A5024434281 @default.
• W4200420384 creator A5025981881 @default.
• W4200420384 creator A5026885177 @default.
• W4200420384 creator A5027569313 @default.
• W4200420384 creator A5030364971 @default.
• W4200420384 creator A5032236372 @default.
• W4200420384 creator A5034013989 @default.
• W4200420384 creator A5035714084 @default.
• W4200420384 creator A5037420857 @default.
• W4200420384 creator A5039865224 @default.
• W4200420384 creator A5041608700 @default.
• W4200420384 creator A5042289415 @default.
• W4200420384 creator A5043303284 @default.
• W4200420384 creator A5049066802 @default.
• W4200420384 creator A5049924319 @default.
• W4200420384 creator A5050858536 @default.
• W4200420384 creator A5052659017 @default.
• W4200420384 creator A5055164165 @default.
• W4200420384 creator A5056821188 @default.
• W4200420384 creator A5059536537 @default.
• W4200420384 creator A5063097215 @default.
• W4200420384 creator A5063278042 @default.
• W4200420384 creator A5063887316 @default.
• W4200420384 creator A5064778502 @default.
• W4200420384 creator A5065004480 @default.
• W4200420384 creator A5070470946 @default.
• W4200420384 creator A5071910268 @default.
• W4200420384 creator A5077138162 @default.
• W4200420384 creator A5079509022 @default.
• W4200420384 creator A5079600078 @default.
• W4200420384 creator A5082819378 @default.
• W4200420384 creator A5082995496 @default.
• W4200420384 creator A5085854620 @default.
• W4200420384 creator A5087082448 @default.
• W4200420384 creator A5088286604 @default.
• W4200420384 date "2022-02-22" @default.
• W4200420384 modified "2023-10-03" @default.
• W4200420384 title "Covid-19 Rates by Time since Vaccination during Delta Variant Predominance" @default.
• W4200420384 cites W3153508314 @default.
• W4200420384 cites W3177895433 @default.
• W4200420384 cites W3177903130 @default.
• W4200420384 cites W3184226105 @default.
• W4200420384 cites W3193601449 @default.
• W4200420384 cites W3198569430 @default.
• W4200420384 cites W3199784607 @default.
• W4200420384 cites W3200299601 @default.
• W4200420384 cites W3201177512 @default.
• W4200420384 cites W3206160409 @default.
• W4200420384 cites W3208049134 @default.
• W4200420384 cites W3209028723 @default.
• W4200420384 cites W3209292288 @default.
• W4200420384 cites W3211197905 @default.
• W4200420384 cites W3211593850 @default.
• W4200420384 cites W3215419690 @default.
• W4200420384 cites W4226208081 @default.
• W4200420384 cites W4226246286 @default.
• W4200420384 cites W4226321964 @default.
• W4200420384 cites W4226376477 @default.
• W4200420384 doi "https://doi.org/10.1056/evidoa2100057" @default.
• W4200420384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37207114" @default.
• W4200420384 hasPublicationYear "2022" @default.
• W4200420384 type Work @default.
• W4200420384 citedByCount "8" @default.
• W4200420384 countsByYear W42004203842022 @default.
• W4200420384 countsByYear W42004203842023 @default.
• W4200420384 crossrefType "journal-article" @default.
• W4200420384 hasAuthorship W4200420384A5000071831 @default.
• W4200420384 hasAuthorship W4200420384A5010709441 @default.
• W4200420384 hasAuthorship W4200420384A5011801139 @default.
• W4200420384 hasAuthorship W4200420384A5012143831 @default.
• W4200420384 hasAuthorship W4200420384A5014583094 @default.
• W4200420384 hasAuthorship W4200420384A5016764092 @default.
• W4200420384 hasAuthorship W4200420384A5017019372 @default.
• W4200420384 hasAuthorship W4200420384A5017417020 @default.
• W4200420384 hasAuthorship W4200420384A5021758604 @default.
• W4200420384 hasAuthorship W4200420384A5023912273 @default.
• W4200420384 hasAuthorship W4200420384A5024434281 @default.
• W4200420384 hasAuthorship W4200420384A5025981881 @default.
• W4200420384 hasAuthorship W4200420384A5026885177 @default.
• W4200420384 hasAuthorship W4200420384A5027569313 @default.
• W4200420384 hasAuthorship W4200420384A5030364971 @default.
• W4200420384 hasAuthorship W4200420384A5032236372 @default.
• W4200420384 hasAuthorship W4200420384A5034013989 @default.
• W4200420384 hasAuthorship W4200420384A5035714084 @default.
• W4200420384 hasAuthorship W4200420384A5037420857 @default.
• W4200420384 hasAuthorship W4200420384A5039865224 @default.
• W4200420384 hasAuthorship W4200420384A5041608700 @default.
• W4200420384 hasAuthorship W4200420384A5042289415 @default.

• next